Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

← Back to all medicines

Prednisolone 10 mg/ml Oral solution

⚠ This medicine appears to have been discontinued

The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.

If you were prescribed this medicine, other products containing Prednisone may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.

Active substance: Prednisone
Source: electronic medicines compendium (emc)
Official leaflet: Read the PIL on emc

What it is and what it is used for

for Your doctor has decided that you or your child, need this medicine to help treat your, or their, condition. Prednisolone 10mg/ml Oral Solution (called Prednisolone Oral Solution throughout the rest of this leaflet) contains the active ingredient prednisolone. Prednisolone belongs to a group of medicines called steroids (the full name is corticosteroids). Corticosteroids occur naturally in the body and help to maintain health and wellbeing. Boosting your body with extra corticosteroid (such as prednisolone) is an effective way to treat various illnesses involving inflammation in the body. Prednisolone Oral Solution reduces this inflammation and lowers the body's immune response, which could otherwise go on making your condition worse. You must take this medicine regularly to get the maximum benefit from it. Prednisolone Oral Solution can be used: y to treat breathing difficulties associated with asthma; y to treat severe allergic reactions; y to treat illnesses which cause inflammation of the skin, small and medium sized arteries, muscles and joints (including rheumatoid arthritis); y to treat problems with your immune system, where the immune system attacks the cells in your body; y to treat certain kidney problems; y to treat certain illnesses resulting in inflammation of the bowels e.g. Bowel diseases such as ulcerative colitis or Crohn's disease; y to treat inflammation of the heart; y to treat problems with your blood including haemolytic anaemia (a disorder which breaks down red blood cells) and leukaemia; y to prevent rejection following an organ transplant.

What you need to know before you take it

e Prednisolone Oral Solution Do not use Prednisolone Oral Solution y if you are allergic to prednisolone or any of the other ingredients of this medicine (listed in section 6). Signs of a severe allergic reaction may include a red and lumpy skin rash, itching, difficulty breathing, swelling of face, mouth, lips , tongue, throat or eyelids, unexplained high temperature (fever) and feeling faint. If the swelling affects your throat and makes breathing and swallowing difficult, go to hospital straight away; y if you have an infection which affects your entire body (unless you are receiving treatment for the infection); y if you have recently had any "live" vaccinations or have a vaccination planned; y if you have a viral infection such as measles, chicken pox or shingles or any other infection. Tell your doctor immediately if you have come into contact with anyone suffering with measles, chicken pox or shingles in the last three months. Warnings and precautions Talk to your doctor, pharmacist or nurse before taking Prednisolone Oral Solution: y if you have or ever had severe depression or manic depressive illness (bipolar disorder). This includes having had depression before or while taking steroid medicines like Prednisolone Oral Solution; y if any of your close family has had these illnesses; y if you have Scleroderma (also known as systemic sclerosis, an autoimmune disorder) because daily doses of 15mg or more may increase the risk of a serious complication called scleroderma renal crisis. Signs of scleroderma renal crisis include increased blood pressure and decreased urine production. The doctor may advise that you have your blood pressure and urine regularly checked. Mental health problems while taking Prednisolone Oral Solution Mental health problems can happen while taking steroids like Prednisolone Oral Solution. y These illnesses can be serious. y Usually they start within a few days or weeks of starting the medicine. y They are more likely to happen at high doses. y Most of these problems go away if the dose is lowered or the medicine is stopped. However, if problems do happen, they might need treatment. Talk to a doctor if you (or someone taking this medicine) show any signs of mental health problems. This is particularly important if you are depressed or might be thinking about suicide. In a few cases, mental health problems have happened when doses are being lowered or stopped altogether. Contact your doctor if you experience blurred vision or other visual disturbances. Children and adolescents The use of steroids can slow down normal growth of children and adolescents which may be irreversible. Chickenpox, shingles or measles y Tell your doctor if you have previously had chickenpox, shingles or measles or if you have been vaccinated against these infections. y It is important that whilst you are taking this medicine, you avoid contact with anybody who has chickenpox, shingles or measles

especially if you have not already had them. If you think you may have come into contact with a person who has chickenpox, shingles or measles, you should contact your doctor immediately. y If you catch chickenpox, shingles or measles, tell your doctor immediately. Your doctor will advise you on how to take prednisolone. Your doctor may want to change your dose of Prednisolone Oral Solution. Please also tell your doctor or pharmacist if any of the following apply to you: y if you have, or have ever had, tuberculosis (TB) or blood poisoning (septicaemia); y if you have liver or kidney problems; y if you have high blood pressure (or a family history of high blood pressure), heart disease or you have recently had a heart attack; y if you have or have a family history of the following:

  • diabetes
  • osteoporosis (thinning of the bones)
  • glaucoma (raised eye pressure)
  • epilepsy (fits); y if you have ever previously suffered from muscle weakness when using prednisolone or any other steroids, in the past; y if you have, or have had, a stomach ulcer; y if you have an underactive thyroid gland (hypothyroidism). If you have any of the above conditions, your doctor may monitor you carefully whilst you are taking this medicine. Other medicines and Prednisolone Oral Solution Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. y Some medicines may increase the effects of Prednisolone Oral Solution and your doctor may wish to monitor you carefully if you are taking these medicines (including some medicines for HIV: ritonavir, cobicistat). y Rifampicin and rifabutin (antibiotics used to treat tuberculosis): taking these medicines with prednisolone may stop prednisolone from working properly. y Carbamazepine, phenytoin, primidone and phenobarbitone (for epilepsy): taking these medicines with prednisolone may stop prednisolone from working properly. y Ephedrine (a nasal decongestant): taking ephedrine with prednisolone may stop prednisolone from working properly. y Aminoglutethimide (anti-cancer treatment): taking this medicine with prednisolone may stop prednisolone from working properly. y Mifepristone (used for termination of pregnancy): taking mifepristone with prednisolone may stop prednisolone from working properly for several days. y Erythromycin (an antibiotic, used to treat infections): if taken with prednisolone, your doctor may need to change your dose of prednisolone or you may experience more side effects. y Ketoconazole (used to treat fungal infections): if taken with prednisolone, your doctor may need to change your dose of prednisolone or you may experience more side effects. y Ciclosporin (used to prevent rejection after transplants): if taken with prednisolone, your doctor may need to change your dose of prednisolone or you may experience more side effects. y Oestrogen hormones including the contraceptive pill: if taken with prednisolone, you may experience more side effects and your doctor may need to change your dose of prednisolone. y Medicines for diabetics such as insulin, glibenclamide or metformin: if taken with prednisolone, then these medicines may not work properly. y Medicines used to treat high blood pressure (e.g. hydralazine): if taken with prednisolone, then these types of medicines may not work properly. y Diuretics also known as water tablets (e.g. bendrofluazide): if taken with prednisolone, then these types of medicine may not work properly. y Somatotropin (a growth hormone): if taken with prednisolone, your medicine may no longer work properly. y Medicines used to treat myasthenia gravis (muscle weakness), such as neostigmine: if taken with prednisolone, these medicines may not work as well. y Medicines used to make x-rays clearer: if taken with prednisolone, these medicines may not work as well. y Anticoagulant medicines which thin the blood (e.g. warfarin and coumarin): if taken with prednisolone, you may be at an increased risk of bleeding, therefore your doctor is likely to monitor you more closely. y Aspirin and Non-Steroidal Anti-Inflammatory Drugs (e.g. ibuprofen): if taken with prednisolone you may be more likely to develop ulcers or bleeding from the stomach. y Salicylates (e.g. Aspirin): if taken with prednisolone you may experience an increase in side effects of the salicylate once you stop taking prednisolone. y Methotrexate (anti-cancer treatment): if taken with prednisolone you may experience more severe side effects. In addition, please tell your doctor or pharmacist if you are taking any of the following medicines, as taking these medicines with Prednisolone Oral Solution may cause you to have a lower level of potassium in your blood than normal (hypokalaemia): y Acetazolamide (used for glaucoma and epilepsy); y Diuretics also known as water tablets e.g. furosemide and bendroflumethiazide (used to treat high blood pressure); y Carbenoxolone (used in the treatment of stomach ulcers); y Medicines used to treat asthma (e.g. theophylline, bambuterol, fenoterol, formoterol, ritodrine, salbutamol, salmeterol and terbutaline); y Amphotericin (used to treat fungal infections). Vaccinations If you have recently had or are planning to have any vaccinations, tell your doctor before taking Prednisolone Oral Solution. Pregnancy, breast-feeding and fertility If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Prednisolone Oral Solution contains sodium methyl parahydroxybenzoate, sodium propyl parahydroxybenzoate and sodium: y Sodium methyl parahydroxybenzoate and sodium propyl parahydroxybenzoate. May cause allergic reactions (possibly delayed). y Sodium. This medicinal product contains 2.5mg of sodium per 1ml oral solution (10mg prednisolone) and 25mg of sodium per 10ml of oral solution (100mg prednisolone) daily. To be taken into consideration by patients on a controlled sodium diet. Driving and using machines This medicine should not affect your ability to drive or use machines. Carrying a Steroid card Your doctor or pharmacist will give you a Steroid Treatment Card with your prescription or medicine. Keep this card with you always as it must be shown to any of the following persons: y Doctor or Nurse – before having any surgery or emergency treatment or if any new treatment is prescribed. y Dentist – before having any dental surgery. y Pharmacist – before buying any medicine. y Optician – it is advisable to have regular eye tests. y Even after your treatment has finished, tell any doctor, dentist, nurse, midwife or anyone else who is giving you treatment that you have taken steroids.

How to take it

Prednisolone Oral Solution Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. These instructions will have been added to the dispensing label by your pharmacist.

Using the syringe A 5ml graduated syringe is provided with your medicine. Use the syringe to withdraw, from the bottle, the amount of Prednisolone Oral Solution that has been prescribed for you by your doctor. y Insert the syringe in the bottle and hold it in place. y Still holding the syringe in place, pull the plunger up until you withdraw the prescribed amount of oral solution. (refer to Figure 1 and Figure 2). y Remove the syringe from the bottle. y After use, close the bottle with its cap and wash the syringe with hot water. Let the syringe dry. Figure 1.

Each graduation of the syringe above the 0.5ml graduation is equivalent to 0.25ml of solution. The lowest dose that can be administered with this syringe is 0.25ml. If you need to take 0.25ml of solution, insert the syringe in the bottle and, holding it in place, pull the plunger up to the 0.75ml graduation. Then, place the syringe above a spoon and push the plunger until the graduation of 0.5 ml. The solution in the spoon corresponds to 0.25ml. Figure 2.

The recommended dose is: Adults y The usual starting dose is 1ml to 10ml per day. y Your doctor may reduce the dose, after a few days or weeks, depending on how well your condition is responding to the treatment. For Rheumatoid Arthritis y The usual starting dose is between 0.75ml and 1ml per day. Use in children and adolescents y Your doctor will decide the most appropriate dose to treat your child. y If Prednisolone Oral Solution has been prescribed for your child, for the treatment of acute asthma attacks the following dosing regime may be given for up to three days:

  • For children over 5 years of age, 3 to 4ml may be prescribed;
  • For children aged 2-5 years of age, 2ml may be prescribed;
  • For children aged under 2 years, 1ml may be prescribed if your child is being treated in a hospital. Important: If you are unsure how much medicine to take, please contact your doctor or pharmacist for advice. Method of administration: For oral use only. If you take more Prednisolone Oral Solution than you should If you take more oral solution than your doctor has told you to, contact a doctor or your nearest hospital casualty department immediately and take this medicine with you to show the doctor what you have taken. If you forget to take Prednisolone Oral Solution y If you forget to take a dose, take it as soon as you remember unless it is almost time for the next dose. y Do not take a double dose to make up for a forgotten dose. If you stop taking Prednisolone Oral Solution Speak to your doctor before you stop taking Prednisolone Oral Solution. y Do not stop taking this medicine suddenly. Your doctor will tell you how to reduce your dose slowly over a number of weeks or months to help lower the chance of you getting withdrawal symptoms. y Stopping Prednisolone Oral Solution (particularly if stopped suddenly) can lead to withdrawal symptoms. The most common are:
  • high temperature
  • muscle and joint pain
  • runny nose
  • weight loss
  • itchy skin
  • red, sore and sticky eyes (conjunctivitis)
  • headache
  • being sick
  • blurred vision
  • low blood pressure. y If you get severe withdrawal symptoms tell your doctor straight away. He/she may ask you to start taking your medicine again and then to start coming off it again more slowly. If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

Possible side effects Like all medicines, this medicine can cause side effects, although not everybody gets them. If you experience any of the following side effects after you have been given your medicine, tell your doctor or pharmacist immediately: y Severe allergic reaction which may include itching or a red and lumpy skin rash, difficulty breathing, or wheeziness, swelling of face, mouth, lips or eyelids, unexplained high temperature (fever) and feeling faint. If the swelling affects your throat and makes breathing and swallowing difficult, go to hospital straight away. y Serious mental health problems. Steroids, including prednisolone, can cause serious mental health problems. These are common in both adults and children. They can affect about five in every 100 people using medicines like prednisolone. The symptoms include:

  • feeling depressed, including thinking about suicide;
  • feeling high (mania) or moods that can go up (euphoric mood) and down;
  • feeling anxious, having problems sleeping, difficulty in thinking or being confused and losing your memory;
  • feeling, seeing or hearing things which do not exist. Having strange and frightening thoughts, changing how you act or have feelings of being alone. y If you have epilepsy and you have more fits than normal. The following side effects may occur if prednisolone is given for a long period of time: Not known (frequency cannot be estimated from the available data). y generally feeling unwell y feeling or being sick (nausea) y hiccups y indigestion or stomach discomfort

y stomach ulcers (which can rupture and bleed) ulcers in the oesophagus (gullet) y diarrhoea y thrush y inflammation of the pancreas causing abdominal pain (pancreatitis) y muscle weakness y muscle pain y thinning of the bones with an increased risk of fractures (osteoporosis) y damage to tendons y joint stiffness causing limited movement, pain and muscle spasms y fluid retention causing swelling y feeling dehydrated y high blood pressure y slow healing of wounds, thinning of the skin, bruising, acne, marks which look like stretch marks y small red, purple or blue spots found along the surface of the skin (caused by blood vessels under the skin) y low adrenal gland function y slowed growth in infants, children and teenagers y irregular periods or your periods may stop altogether y excess hair growth y increased appetite and weight gain y increased sweating y intolerance to carbohydrates y loss of protein and calcium balance y dizziness y severe headaches with blurred vision or temporary visual problems in children (usually after stopping treatment) y worsening of epilepsy y increased pressure in the eye (glaucoma), swelling in the eye, cataracts, thinning and inflammation of the eye membranes, worsening of viral or fungal eye diseases y vertigo (sensation of spinning) y heart attack (sudden severe chest pains) y tearing of the heart muscle tissues, particularly if you have recently had a heart attack y slow heart rate y changes in body chemistry (salt imbalances: sodium and potassium salts) y raised level of white blood cells y formation of blood clots y blocked blood vessel (embolism) y blurred vision y detachment of the retina causing visual impairment y protrusion of the eyeballs y scleroderma renal crisis in patients already suffering from scleroderma (an autoimmune disorder). Signs of scleroderma renal crisis include increased blood pressure and decreased urine production y long term use of high dose steroids, may lead to a weakening of the immune system, which can increase the risk of malignancy. Kaposi's sarcoma (a type of cancer consisting of raised, red, purple or brown skin lesion) has also been reported to occur in patients receiving corticosteroids. Stopping treatment may alleviate these symptoms. Prednisolone Oral Solution can make it easier for you to pick up infections which may very rarely be fatal. Infections such as chicken pox and measles can be made worse, or TB (tuberculosis) may recur. Additional side effects in children and adolescents Children and teenagers taking this medicine may grow more slowly than normal. If you, as the patient or carer, are worried about the effects of taking this medicine, go back and discuss it with your doctor. Elderly If you are elderly, your doctor will monitor you closely whilst you are taking this medicine as you may be more likely to experience

Possible side effects

. Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

How to store it

Prednisolone Oral Solution Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the carton and label after EXP. The expiry date refers to the last day of that month. Store in a refrigerator (2°C – 8°C). Once opened, your medicine should be used within 3 months and stored in a refrigerator. Store in the original package in order to protect from light. Do not use this medicine if you notice any visible signs of damage to the bottle or deterioration in your medicine. Return it to your pharmacist. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.

Contents of the pack and other information

What Prednisolone Oral Solution contains The active substance is prednisolone. Each 1ml of oral solution contains 10mg prednisolone (as prednisolone sodium phosphate). The other ingredients are: glycerol, xylitol, sucralose, sodium dihydrogen phosphate dihydrate, disodium phosphate dihydrate, orange flavour, vanilla cream flavour, sodium methyl parahydroxybenzoate (E219), sodium propyl parahydroxybenzoate (E217), disodium edetate, sodium hydroxide and/or hydrochloric acid (as pH adjusters) and purified water. What Prednisolone Oral Solution looks like and contents of the pack Prednisolone 10mg/ml Oral Solution is a clear, colourless to yellowish oral solution with a characteristic odour of orange. It is available in an amber glass bottle containing 30ml of medicine. The pack also contains a 5ml plastic oral dosing syringe. Marketing Authorisation Holder Aspire Pharma Limited Unit 4, Rotherbrook Court Bedford Road, Petersfield Hampshire, GU32 3QG United Kingdom Manufacturer MEDICAIR BIOSCIENCE LABORATORIES S.A. 61st km National Road Athinon-Lamias Sximatari Viotias, 32009 Greece This leaflet was last revised in 12/2025.

To request a copy of this leaflet in Braille, large print or audio please call 0800 198 5000 (UK only). Please be ready to give the following information: Product name: Prednisolone 10mg/ml Oral Solution Reference number: PL 35533/0326

1010715 – P2.1

0000000000

Your doctor will decide on the most appropriate dose to treat you or your child.

Artwork for: Product name: Size: PL/PA no: Type: Artwork dimensions: Reason for request: Version no: Date of revision: Colours: Font(s): A/W software:

Aspire Pharma Limited Prednisolone 10mg/ml Oral Solution 30ml PL35533/0326 Leaflet 190mm x 500mm Var IB – Update text 2.1 10.12.25 As swatches Strada Pro Condensed Indesign CC

Black

Frequently asked questions about Prednisolone 10 mg/ml Oral solution

How do I take Prednisolone 10 mg/ml Oral solution?

Prednisolone 10 mg/ml Oral solution comes as oral solution containing 10mg/ml. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.

What is the active substance in Prednisolone 10 mg/ml Oral solution?

The active substance in Prednisolone 10 mg/ml Oral solution is prednisone.

Where does this information come from?

This leaflet reproduces the patient information leaflet approved for Prednisolone 10 mg/ml Oral solution, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.

Can I get Prednisolone 10 mg/ml Oral solution without a prescription?

Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.

About this leaflet

The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.

Medical disclaimer: This page is for information only and does not replace advice from your doctor or pharmacist. Always read the leaflet supplied with your medicine. If you are unwell, call NHS 111; in an emergency, call 999.

Medicines with the same active substance: Prednisone (1 medicine)
See every medicine containing this substance, or browse the full A–Z of active substances.
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
Technical information intended for healthcare professionals (doctors and pharmacists). The Summary of Product Characteristics (SmPC) is the official document approved by the MHRA/EMA. It does not replace the patient leaflet or a doctor’s advice.

4.1. Therapeutic indications

A wide variety of diseases may sometimes require corticosteroid therapy. Some of the principal indications are:

• bronchial asthma, severe hypersensitivity reactions, anaphylaxis; rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis, mixed connective tissue disease (excluding systemic sclerosis), polyarteritis nodosa;

• inflammatory skin disorders, including pemphigus vulgaris, bullous pemphigoid and pyoderma gangrenosum;

• minimal change nephrotic syndrome, acute interstitial nephritis;

• ulcerative colitis, Crohn's disease; sarcoidosis;

• rheumatic carditis;

• haemolytic anaemia (autoimmune), acute lymphoblastic and chronic lymphocytic leukaemia, malignant lymphoma, multiple myeloma, idiopathic thrombocytopenic purpura;

• immunosuppression in transplantation.

4.2. Posology and method of administration

Posology

The lowest dosage that will produce an acceptable result should be used (see section 4.4); when it is possible to reduce the dosage, this must be accomplished by stages. During prolonged therapy any intercurrent illness, trauma or surgical procedure will require a temporary increase in dosage; if corticosteroids have been stopped following prolonged therapy they may need to be temporarily re-introduced.

Adults: The dose used will depend upon the disease, its severity and the clinical response obtained. The following regimens are for guidance only. Divided dosage is usually employed.

Short-term treatment: 20mg (2ml) to 30mg (3ml) daily for the first few days, subsequently reducing the daily dosage by 2.5mg (0.25ml) or 5mg (0.5ml) every two to five days, depending upon the response.

Rheumatoid arthritis: 7.5mg (0.75ml) to 10mg (1ml) daily. For maintenance therapy the lowest effective dosage is used.

Most other conditions: 10mg (1ml) to 100mg (10ml) daily for one to three weeks, then reducing to the minimum effective dosage.

Paediatric population: Fractions of the adult dosage may be used (e.g. 75% at 12 years, 50% at 7 years and 25% at 1 year) but clinical factors must be given due weight.

Prednisolone may be given early in the treatment of acute asthma attacks in children.

For children over 5 years use a dose of 30-40mg (3-4ml) prednisolone.

For children aged 2-5 years use a dose of 20mg (2ml) prednisolone. Those already receiving maintenance steroid tablets should receive 2mg/kg prednisolone up to a maximum dose of 60mg (6ml). The dose of prednisolone may be repeated for children who vomit; but intravenous steroids should be considered in children who are unable to retain orally ingested medication. Treatment for up to three days is usually sufficient, but the length of course should be tailored to the number of days necessary to bring about recovery. There is no need to taper the dose at the end of treatment.

For children under 2 years, Prednisolone can be used early in the management of moderate to severe episodes of acute asthma in the hospital setting, at a dose of 10mg (1ml) for up to three days.

Method of administration: Oral

4.3. Contraindications

• Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

• Systemic infections, unless specific anti-infective therapy is employed.

• Live virus immunisation.

4.4. Special warnings and precautions for use

In patients who have received more than physiological doses of systemic corticosteroids (approximately 7.5mg prednisolone or equivalent) for greater than three weeks, withdrawal should not be abrupt. How dose reduction should be carried out depends largely on whether the disease is likely to relapse as the dose of systemic corticosteroids is reduced. Clinical assessment of disease activity may be needed during withdrawal. If the disease is unlikely to relapse on withdrawal of systemic corticosteroids but there is uncertainty about HPA suppression, the dose of systemic corticosteroid may be reduced rapidly to physiological doses. Once a daily dose equivalent to 7.5mg (0.75ml) prednisolone is reached, dose reduction should be slower to allow the HPA axis to recover.

Abrupt withdrawal of systemic corticosteroid treatment, which has continued up to three weeks is appropriate if it is considered that the disease is unlikely to relapse. Abrupt withdrawal of doses of up to 40mg daily of prednisolone or equivalent for three weeks is unlikely to lead to clinically relevant HPA axis suppression, in the majority of patients. In the following patient groups, gradual withdrawal of systemic corticosteroid therapy should be considered even after courses lasting three weeks or less:

• Patients who have had repeated courses of systemic corticosteroids, particularly if taken for greater than three weeks.

• When a short course has been prescribed within one year of cessation of long-term therapy (months or years).

• Patients who may have reasons for adrenocortical insufficiency other than exogenous corticosteroid therapy, been stopped following prolonged therapy they may need to be temporarily reintroduced.

• Patients receiving doses of systemic corticosteroid greater than 40mg daily of prednisolone (or equivalent).

• Patients repeatedly taking doses in the evening.

Patients should carry 'steroid treatment' cards which give clear guidance on the precautions to be taken to minimise risk and which provide details of the prescriber, drug, dosage and the duration of treatment.

Adrenal cortical atrophy develops during prolonged therapy and may persist for years after stopping treatment. Withdrawal of corticosteroids after prolonged therapy must therefore always be gradual to avoid acute adrenal insufficiency, being tapered off over weeks or months according to the dose and duration of treatment. During prolonged therapy any intercurrent illness, trauma or surgical procedure will require a temporary increase in dosage; if corticosteroids have been stopped following prolonged therapy they may need to be temporarily re-introduced.

Suppression of the HPA axis and other undesirable effects may be minimised by using the lowest effective dose for the minimum period and by administering the daily requirement as a single morning dose or whenever possible as a single morning dose on alternate days. Frequent patient review is required to appropriately titrate the dose against disease activity (see section 4.2).

Visual disturbance

Visual disturbance may be reported with systemic and topical corticosteroid use. If a patient presents with symptoms such as blurred vision or other visual disturbances, the patient should be considered for referral to an ophthalmologist for evaluation of possible causes which may include cataract, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR) which have been reported after use of systemic and topical corticosteroids.

Suppression of the inflammatory response and immune function increases the susceptibility to infections and their severity. The resultant opportunistic infections may be fatal. The clinical presentation may often be atypical and serious infections such as septicaemia and tuberculosis may be masked and may reach an advanced stage before being recognised.

Chickenpox is of particular concern since this normally minor illness may be fatal in immunosuppressed patients. Patients without a definite history of chickenpox should be advised to avoid close personal contact with chickenpox or herpes zoster and if exposed they should seek urgent medical attention. If the patient is a child parents must be given the above advice. Passive immunisation with varicella zoster immunoglobulin (VZIG) is needed by exposed non-immune patients who are receiving systemic corticosteroids or who have used them within the previous three months; this should be given within 10 days of exposure to chickenpox. If a diagnosis of chickenpox is confirmed, the illness warrants specialist care and urgent treatment.

Corticosteroids should not be stopped and the dose may need to be increased.

Patients should be advised to take particular care to avoid exposure to measles and to seek immediate advice if exposure occurs. Prophylaxis with intramuscular normal immunoglobulin may be needed.

Live vaccines should not be given to individuals with impaired immune responsiveness caused by high doses of corticosteroids. The antibody response to other vaccines may be diminished.

Kaposi's sarcoma has been reported to occur in patients receiving corticosteroid therapy. Discontinuation of corticosteroids may result in clinical remission.

Chronic immunosuppression (e.g. in the setting of organ transplantation), has been associated with an increased risk of malignancy.

Because of the possibility of fluid retention, care must be taken when corticosteroids are administered to patients with renal insufficiency or hypertension or congestive heart failure.

Corticosteroids may worsen diabetes mellitus, osteoporosis, hypertension, glaucoma and epilepsy and therefore patients with these conditions or a family history of them should be monitored frequently.

Care is required and frequent patient monitoring necessary where there is a history of severe affective disorders (especially a previous history of steroid psychosis), previous steroid myopathy, peptic ulceration, hypothyroidism, recent myocardial infarction or patients with a history of tuberculosis.

In patients with liver failure, blood levels of corticosteroid may be increased, as with other drugs which are metabolised in the liver. Frequent patient monitoring is therefore necessary.

Paediatric population: Corticosteroids cause dose-related growth retardation in infancy, childhood and adolescence, which may be irreversible.

Use in the Elderly: The common adverse effects of systemic corticosteroids may be associated with more serious consequences in old age, especially osteoporosis, hypertension, hypokalaemia, diabetes, susceptibility to infection and thinning of the skin. Close clinical supervision is required to avoid life-threatening reactions.

Patients and/or carers should be warned that potentially severe psychiatric adverse reactions may occur with systemic steroids (see section 4.8). Symptoms typically emerge within a few days or weeks of starting the treatment. Risks may be higher with high doses/systemic exposure (see also section 4.5), although dose levels do not allow prediction of the onset, type, severity or duration of reactions. Most adverse reactions resolve after either dose reduction or withdrawal of the medicine, although specific treatment may be necessary. Patients/carers should be encouraged to seek medical advice if worrying psychological symptoms develop, especially if depressed mood or suicidal ideation is suspected. Patients/carers should also be alert to possible psychiatric disturbances that may occur either during or immediately after dose tapering/withdrawal of systemic steroids, although such reactions have been reported infrequently.

Particular care is required when considering the use of systemic corticosteroids in patients with existing or a previous history of severe affective disorders in themselves or in their first degree relatives. These would include depressive or manic-depressive illness and previous steroid psychosis.

Scleroderma renal crisis

Caution is required in patients with systemic sclerosis because of an increased incidence of (possibly fatal) scleroderma renal crisis with hypertension and decreased urinary output observed with a daily dose of 15 mg or more prednisolone. Blood pressure and renal function (s-creatinine) should therefore be routinely checked. When renal crisis is suspected, blood pressure should be carefully controlled.

Excipients warning:

Prednisolone oral solution contains sodium methyl parahydroxybenzoate and sodium propyl parahydroxybenzoate and may cause allergic reactions (possibly delayed).

It also contains approximately 3mg of sodium per 1ml of oral solution (10mg prednisolone) and 30mg sodium per 10ml of oral solution (100mg prednisolone). To be taken into consideration by patients on a controlled sodium diet.

4.5. Interaction with other medicinal products and other forms of interaction

Co-treatment with CYP3A inhibitors, including cobicistat-containing products, is expected to increase the risk of systemic side-effects. The combination should be avoided unless the benefit outweighs the increased risk of systemic corticosteroid side-effects, in which case patients should be monitored for systemic corticosteroid side-effects.

Rifampicin, rifabutin, carbamazepine, phenobarbitone, phenytoin, primidone, ephedrine and aminoglutethimide enhance the metabolism of corticosteroids and its therapeutic effects may be reduced.

Mifepristone may reduce the effect of corticosteroids for 3-4 days.

Erythromycin and ketoconazole may inhibit the metabolism of some corticosteroids.

Ciclosporin increases plasma concentration of prednisolone. The same effect is possible with ritonavir.

Oestrogens and other oral contraceptives may potentiate the effects of glucocorticoids and dosage adjustments may be required if oral contraceptives are added to or withdrawn from a stable dosage regimen.

The desired effects of hypoglycemic agents (including insulin), anti-hypertensives and diuretics are antagonised by corticosteroids.

The growth promoting effect of somatotropin may be inhibited by the concomitant use of corticosteroids.

Steroids may reduce the effects of anticholinesterases in myasthenia gravis and cholecystographic x-ray media.

The efficacy of coumarin anticoagulants and warfarin may be enhanced by concurrent corticosteroid therapy and close monitoring of the INR or prothrombin time is required to avoid spontaneous bleeding.

Concomitant use of aspirin and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) with corticosteroids increases the risk of gastro-intestinal bleeding and ulceration.

The renal clearance of salicylates is increased by corticosteroids and steroid withdrawal may result in salicylate intoxication.

The hypokalaemic effects of acetazolamide, loop diuretics, thiazide diuretics, and carbenoxolone, are enhanced by corticosteroids. The risk of hypokalaemia is increased with theophylline and amphotericin. Corticosteroids should not be given concomitantly with amphotericin, unless required to control reactions.

The risk of hypokalaemia also increases if high doses of corticosteroids are given with high doses of bambuterol, fenoterol, formoterol, ritodrine, salbutamol, salmeterol and terbutaline. The toxicity of cardiac glycosides is increased if hypokalaemia occurs with corticosteroids.

Concomitant use with methotrexate may increase the risk of haematological toxicity.

High doses of corticosteroids impair the immune response and so live vaccines should be avoided (see also section 4.4).

4.6. Fertility, pregnancy and lactation

Pregnancy

The ability of corticosteroids to cross placenta varies between individual drugs, however, 88% of prednisolone is inactivated as it crosses the placenta.

Administration of corticosteroids to pregnant animals can cause abnormalities of foetal development including cleft palate, intra-uterine growth retardation and effects on brain growth and development. There is no evidence that corticosteroids result in an increased incidence of congenital abnormalities, such as cleft palate / lip in man. However, when administered for prolonged periods or repeatedly during pregnancy, corticosteroids may increase the risk of intrauterine growth retardation.

Hypoadrenalism may, in theory, occur in the neonate following prenatal exposure to corticosteroids but usually resolves spontaneously following birth and is rarely clinically important. As with all drugs, corticosteroids should only be prescribed when the benefits to the mother and child outweigh the risks. When corticosteroids are essential however, patients with normal pregnancies may be treated as though they were in the non-gravid state.

Patients with pre-eclampsia or fluid retention require close monitoring.

Depression of hormone levels has been described in pregnancy but the significance of this finding is not clear.

Breast-feeding

Corticosteroids are excreted in small amounts in breast milk. However, doses of up to 40mg daily of prednisolone are unlikely to cause systemic effects in the infant. Infants of mothers taking higher doses than this may have a degree of adrenal suppression but the benefits of breast-feeding are likely to outweigh any theoretical risk.

Fertility

Corticosteroids may cause irregular menstruation or amenorrhoea.

4.7. Effects on ability to drive and use machines

Prednisolone has no or negligible influence on the ability to drive and use machines.

4.8. Undesirable effects

The incidence of predictable undesirable effects, including hypothalamo-pituitary-adrenal (HPA) suppression, correlates with the relative potency of the drug, dosage, timing of administration and the duration of treatment (see section 4.4).

The following side effects may be associated with the long-term systemic use of corticosteroids with the following frequency:

Not known (cannot be estimated from available data)

System organ class

Frequency

Undesirable effects

Infections and infestations

Not known

Increased susceptibility and severity of infections with suppression of clinical symptoms and signs, opportunistic infections, recurrence of dormant tuberculosis (see section 4.4). Candidiasis

Neoplasms benign, malignant and unspecified (including cysts and polyps)

Not known

Kaposi's sarcoma has been reported to occur in patients receiving corticosteroid therapy. Discontinuation of corticosteroids may result in clinical remission.

Blood and lymphatic system disorders

Not known

Leukocytosis

Immune system disorders

Not known

Hypersensitivity including anaphylaxis.

Endocrine disorders

Not known

Suppression of the HPA axis.

Cushingoid facies.

Impaired carbohydrate intolerance with increased requirement for anti-diabetic therapy, manifestation of latent diabetes mellitus.

Metabolism and nutrition disorders

Not known

Sodium and fluid retention, hypokalaemia, hypokalaemic alkalosis, increased appetite, negative protein and calcium balance.

Psychiatric disordersa

Not known

Euphoric mood, psychological dependence, depressed mood, insomnia, aggravation of schizophrenia.

Nervous system disorders

Not known

Increased intracranial pressure with papilloedema in children (pseudotumor cerebri) -usually after treatment withdrawal.

Dizziness, headache.

Aggravation of epilepsy.

Eye disorders

Not known

Glaucoma, papilloedema, posterior subcapsular cataracts, central serous chorioretinopathy, exophthalmos, corneal or scleral thinning, exacerbation of ophthalmic viral or fungal diseases and vision, blurred (see also section 4.4).

Ear and labyrinth disorders

Not known

Vertigo

Cardiac disorders

Not known

Myocardial rupture following recent myocardial infarction.

Congestive cardiac failure (in susceptible patients).

Bradycardia*

Vascular disorders

Not known

Hypertension, embolism.

Respiratory, thoracic and mediastinal disorders

Not known

Hiccups

Gastrointestinal disorders

Not known

Dyspepsia, nausea, vomiting, abdominal distension, abdominal pain, diarrhoea. Pancreatitis acute, oesophageal ulcer.

Peptic ulceration with perforation and haemorrhage.

Skin and subcutaneous tissue disorders

Not known

Skin Atrophy, skin striae, acne, telangiectasia, hyperhidrosis, rash, pruritus, urticaria, hirsutism.

Musculoskeletal and connective tissue disorders

Not known

Myopathy, osteoporosis, vertebral and long bone fractures, avascular osteonecrosis, myalgia. Growth retardation in infancy, childhood and adolescence.

Renal and urinary disorders

Not known

Scleroderma renal crisisb

Reproductive system and breast disorders

Not known

Menstruation irregular, amenorrhoea.

General disorders and administration site conditions

Not known

Impaired healing, malaise.

Investigations

Not known

Weight increased.

Injury, poisoning and procedural complications

Not known

Tendon rupture, contusion (bruising).

*Following high doses

a) A wide range of psychiatric reactions including affective disorders (such as irritable, euphoric, depressed and labile mood and suicidal thoughts), psychotic reactions (including mania, delusions, hallucinations and aggravation of schizophrenia), behavioural disturbances, irritability, anxiety, sleep disturbances, and cognitive dysfunction including confusion and amnesia have been reported. Reactions are common and may occur in both adults and children. In adults, the frequency of severe reactions has been estimated to be 5-6%. Psychological effects have been reported on withdrawal of corticosteroids; the frequency is unknown.

b) Scleroderma renal crisis

Amongst the different subpopulations the occurrence of scleroderma renal crisis varies. The highest risk has been reported in patients with diffuse systemic sclerosis. The lowest risk has been reported in patients with limited systemic sclerosis (2%) and juvenile onset systemic sclerosis (1%)

Withdrawal Symptoms

Too rapid a reduction of corticosteroid dosage following prolonged treatment can lead to acute adrenal insufficiency, hypotension and death (see section 4.4).

A 'withdrawal syndrome' may also occur including fever, myalgia, arthralgia, rhinitis, conjunctivitis, painful itchy skin nodules and loss of weight.

In some instances, withdrawal symptoms may involve or resemble a clinical relapse of the disease for which the patient has been undergoing treatment.

Other effects that may occur during withdrawal or change of corticosteroid therapy include benign intracranial hypertension with headache and vomiting and papilloedema caused by cerebral oedema.

Latent rhinitis or eczema may be unmasked.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.

4.9. Overdose

Management

Supportive and symptomatic therapy is indicated. Serum electrolytes should be monitored.

High systemic doses of corticosteroids caused by chronic use have been associated with adverse events such as neuropsychiatric disorders (psychosis, depression, hallucinations), cardiac dysrhythmias and Cushing's syndrome.

🇷🇴 Known in Romania as

Medicines sold in Romania with the same active substance: Cunoscut în România ca

  • PREDNISON ARENA 5 mg prescriptionPREDNISONUM · taken by mouth
  • PREDNISONA-RICHTER 5 mg prescriptionPREDNISONUM · taken by mouth
  • PREDNISON MCC 5 mg prescriptionPREDNISONUM · taken by mouth
  • PREDNISON SINTOFARM 5 mg prescriptionPREDNISONUM · taken by mouth

Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Romanian medicines in the UK →

🇵🇱 Known in Poland as

Medicines sold in Poland with the same active substance: W Polsce znany jako

  • EncortonPrednisonum · taken by mouth
  • MedoxaPrednisonum · taken by mouth
  • EsotkalenoPrednisonum · taken by mouth

Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →

💬 Ask about this leaflet

Ask anything about Prednisolone 10 mg/ml Oral solution. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.

Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.

Pharmacies in major towns and cities — see the list
Pharmacies by county and region — see the full list

Browse all 2,009 towns and cities →